2 studies on Antiproliferative mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**GHRH antagonism via JMR-132 may represent a receptor-status-agnostic therapeutic axis in breast cancer**, addressing a major clinical gap: ER-negative tumors have few hormone-based treatment options. The dual activi…
**Peptidyl GHS compounds like hexarelin may carry direct anticancer activity in lung carcinoma independent of their GH-releasing function**, a mechanistic split with major implications for therapeutic development and …